Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Agios Pharmaceuticals Inc AGIO

Healthcare Biotechnology

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined... see more

Add To Watchlist

Recent & Breaking News (NDAQ:AGIO)

Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021

GlobeNewswire July 15, 2021

Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

GlobeNewswire June 28, 2021

Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency

GlobeNewswire June 22, 2021

Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

GlobeNewswire June 21, 2021

Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent ?- and ?-Thalassemia at the European Hematology Association Virtual Congress

GlobeNewswire June 11, 2021

Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress

GlobeNewswire June 11, 2021

Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress

GlobeNewswire May 12, 2021

Agios Reports Business Highlights and First Quarter 2021 Financial Results

GlobeNewswire April 29, 2021

Agios Announces Closing of Oncology Business Sale to Servier

GlobeNewswire April 1, 2021

Agios Shareholders Approve Sale of Oncology Business to Servier

GlobeNewswire March 25, 2021

Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease

GlobeNewswire March 18, 2021

Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

GlobeNewswire March 1, 2021

Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias

GlobeNewswire February 26, 2021

Agios Reports Fourth Quarter and Full Year 2020 Financial Results

GlobeNewswire February 25, 2021

Agios to Present at March Investor Conferences

GlobeNewswire February 23, 2021

Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021

GlobeNewswire February 11, 2021

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

GlobeNewswire January 26, 2021

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

GlobeNewswire January 17, 2021

Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation

GlobeNewswire January 11, 2021

Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021

GlobeNewswire January 5, 2021